Abstract 437P
Background
Physician burnout negatively affects patient care, incurs added costs, and compromises the physician’s own safety. In the field of Medical Oncology, the demands entailed in caring for cancer patients combined with broader pressures on the healthcare system may present significant challenges for both physicians and nurses, including the risk for burnout. This study aims to determine the prevalence of burnout among Medical Oncology fellows-in-training in the Philippines, as well as identify which of the domains of burnout are commonly experienced by the fellows-in-training.
Methods
This is a descriptive cross-sectional study evaluating the prevalence of burnout among Medical Oncology fellows-in-training using the Maslach Burnout Inventory (MBI).
Results
Out of 70 Medical Oncology fellows-in-training, 50 participated in the survey. Most of the fellows-in-training were experiencing some degree of burnout during the conduct of the study. Fifty four percent (27) felt a high level of emotional exhaustion, while 38% (19) and 42% (21) felt a moderate level of burnout in the depersonalization and personal accomplishment domains respectively. Overall, 94% of respondents had a moderate to high level of burnout.
Conclusions
Physician burnout remains to be a considerable problem among Medical Oncology fellows-in-training in the Philippines. Majority of respondents experienced a moderate to high level of burnout, most commonly in the emotional exhaustion domain. Vacation leaves, recreational and wellness activities, and decreased work hours are some of the interventions cited to help reduce physician burnout.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
399P - Role of denosumab as targeted therapy in treatment of unresectable or recurrent cases of giant cell tumor of the bone
Presenter: Anchal Mishra
Session: Poster viewing 06
400P - Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)
Presenter: Omid Hamid
Session: Poster viewing 06
401P - A phase Ib study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in combination with lenvatinib in patients (pts) with advanced solid tumors
Presenter: Shunsuke Kondo
Session: Poster viewing 06
402P - Phase I study of selumetinib in Chinese pediatric and adult patients (pts) with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN): Interim results
Presenter: Xiao-Jun Yuan
Session: Poster viewing 06
403P - Gender trend over time of principal investigators within large Australian cancer clinical trials groups
Presenter: Thi Thao Vi Luong
Session: Poster viewing 06
404P - Adolescent & young adult cancers (AYA): Experience from a large rural teaching hospital in South India
Presenter: Vishwapriya Godkhindi
Session: Poster viewing 06
405P - Evaluating medical oncology outcomes (EMOO) in Asia study: Diagnosis, staging, treatment patterns and outcome of patients with lung cancer registered 2017-2019
Presenter: Ross Soo
Session: Poster viewing 06
406P - Adrenal insufficiency induced by immune checkpoint inhibitors: Clinical characteristics of 145 cases
Presenter: kaoru koshiba
Session: Poster viewing 06
407P - A post-marketing surveillance of the real-world safety and effectiveness of avelumab in patients with curatively unresectable Merkel cell carcinoma in Japan
Presenter: Naoya Yamazaki
Session: Poster viewing 06
408P - Machine learning for glioblastoma screening from histopathology whole slide imaging
Presenter: Eva Yi Wah Cheung
Session: Poster viewing 06